| Literature DB >> 32506714 |
Massimo Filippi1,2,3,4, Paolo Preziosa1,2, Dawn Langdon5, Hans Lassmann6, Friedemann Paul7, Àlex Rovira8, Menno M Schoonheim9, Alessandra Solari10, Bruno Stankoff11, Maria A Rocca1,2.
Abstract
The identification of progression in multiple sclerosis is typically retrospective. Given the profound burden of progressive multiple sclerosis, and the recent development of effective treatments for these patients, there is a need to establish measures capable of identifying progressive multiple sclerosis early in the disease course. Starting from recent pathological findings, this review assesses the state of the art of potential measures able to predict progressive multiple sclerosis. Future promising biomarkers that might shed light on mechanisms of progression are also discussed. Finally, expansion of the concept of progressive multiple sclerosis, by including an assessment of cognition, patient-reported outcomes, and comorbidities, is considered. ANN NEUROL 2020;88:438-452.Entities:
Mesh:
Year: 2020 PMID: 32506714 DOI: 10.1002/ana.25808
Source DB: PubMed Journal: Ann Neurol ISSN: 0364-5134 Impact factor: 10.422